These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38960100)

  • 21. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions.
    Guo Q; Ho HT; Dicker I; Fan L; Zhou N; Friborg J; Wang T; McAuliffe BV; Wang HG; Rose RE; Fang H; Scarnati HT; Langley DR; Meanwell NA; Abraham R; Colonno RJ; Lin PF
    J Virol; 2003 Oct; 77(19):10528-36. PubMed ID: 12970437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.
    Esser MT; Mori T; Mondor I; Sattentau QJ; Dey B; Berger EA; Boyd MR; Lifson JD
    J Virol; 1999 May; 73(5):4360-71. PubMed ID: 10196334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lineage-specific differences between human and simian immunodeficiency virus regulation of gp120 trimer association and CD4 binding.
    Finzi A; Pacheco B; Xiang SH; Pancera M; Herschhorn A; Wang L; Zeng X; Desormeaux A; Kwong PD; Sodroski J
    J Virol; 2012 Sep; 86(17):8974-86. PubMed ID: 22696649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense® Entry assay.
    Gartland M; Zhou N; Stewart E; Pierce A; Clark A; Ackerman P; Llamoso C; Lataillade M; Krystal M
    J Antimicrob Chemother; 2021 Feb; 76(3):648-652. PubMed ID: 33241285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stabilization of HIV-1 gp120-CD4 receptor complex through targeted interchain disulfide exchange.
    Cerutti N; Mendelow BV; Napier GB; Papathanasopoulos MA; Killick M; Khati M; Stevens W; Capovilla A
    J Biol Chem; 2010 Aug; 285(33):25743-52. PubMed ID: 20538591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Temsavir Treatment of HIV-1-Infected Cells Decreases Envelope Glycoprotein Recognition by Broadly Neutralizing Antibodies.
    Boutin M; Vézina D; Ding S; Prévost J; Laumaea A; Marchitto L; Anand SP; Medjahed H; Gendron-Lepage G; Bourassa C; Goyette G; Clark A; Richard J; Finzi A
    mBio; 2022 Jun; 13(3):e0057722. PubMed ID: 35475646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist.
    Courter JR; Madani N; Sodroski J; Schön A; Freire E; Kwong PD; Hendrickson WA; Chaiken IM; LaLonde JM; Smith AB
    Acc Chem Res; 2014 Apr; 47(4):1228-37. PubMed ID: 24502450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043.
    Zhou N; Nowicka-Sans B; Zhang S; Fan L; Fang J; Fang H; Gong YF; Eggers B; Langley DR; Wang T; Kadow J; Grasela D; Hanna GJ; Alexander L; Colonno R; Krystal M; Lin PF
    Antimicrob Agents Chemother; 2011 Feb; 55(2):729-37. PubMed ID: 21078948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1.
    Dogo-Isonagie C; Lam S; Gustchina E; Acharya P; Yang Y; Shahzad-ul-Hussan S; Clore GM; Kwong PD; Bewley CA
    J Biol Chem; 2012 Apr; 287(18):15076-86. PubMed ID: 22403408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
    Wyatt R; Moore J; Accola M; Desjardin E; Robinson J; Sodroski J
    J Virol; 1995 Sep; 69(9):5723-33. PubMed ID: 7543586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
    Reeves JD; Gallo SA; Ahmad N; Miamidian JL; Harvey PE; Sharron M; Pohlmann S; Sfakianos JN; Derdeyn CA; Blumenthal R; Hunter E; Doms RW
    Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16249-54. PubMed ID: 12444251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Species-Specific Valid Ternary Interactions of HIV-1 Env-gp120, CD4, and CCR5 as Revealed by an Adaptive Single-Amino Acid Substitution at the V3 Loop Tip.
    Koma T; Yokoyama M; Kotani O; Doi N; Nakanishi N; Okubo H; Adachi S; Adachi A; Sato H; Nomaguchi M
    J Virol; 2021 Jun; 95(13):e0217720. PubMed ID: 33883222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transitions to and from the CD4-bound conformation are modulated by a single-residue change in the human immunodeficiency virus type 1 gp120 inner domain.
    Kassa A; Madani N; Schön A; Haim H; Finzi A; Xiang SH; Wang L; Princiotto A; Pancera M; Courter J; Smith AB; Freire E; Kwong PD; Sodroski J
    J Virol; 2009 Sep; 83(17):8364-78. PubMed ID: 19535453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis, antiviral activity and resistance of a novel small molecule HIV-1 entry inhibitor.
    Curreli F; Haque K; Xie L; Qiu Q; Xu J; Yong W; Tong X; Debnath AK
    Bioorg Med Chem; 2015 Dec; 23(24):7618-28. PubMed ID: 26602829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Probing the Structure of the HIV-1 Envelope Trimer Using Aspartate Scanning Mutagenesis.
    Das R; Datta R; Varadarajan R
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32817217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.
    Nakamura GR; Byrn R; Wilkes DM; Fox JA; Hobbs MR; Hastings R; Wessling HC; Norcross MA; Fendly BM; Berman PW
    J Virol; 1993 Oct; 67(10):6179-91. PubMed ID: 7690420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In Silico Identification of Novel Aromatic Compounds as Potential HIV-1 Entry Inhibitors Mimicking Cellular Receptor CD4.
    Andrianov AM; Nikolaev GI; Kornoushenko YV; Xu W; Jiang S; Tuzikov AV
    Viruses; 2019 Aug; 11(8):. PubMed ID: 31412617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.
    Moseri A; Biron Z; Arshava B; Scherf T; Naider F; Anglister J
    FEBS J; 2015 Dec; 282(24):4643-57. PubMed ID: 26432362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Local conformational stability of HIV-1 gp120 in unliganded and CD4-bound states as defined by amide hydrogen/deuterium exchange.
    Kong L; Huang CC; Coales SJ; Molnar KS; Skinner J; Hamuro Y; Kwong PD
    J Virol; 2010 Oct; 84(19):10311-21. PubMed ID: 20660185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155.
    Madani N; Perdigoto AL; Srinivasan K; Cox JM; Chruma JJ; LaLonde J; Head M; Smith AB; Sodroski JG
    J Virol; 2004 Apr; 78(7):3742-52. PubMed ID: 15016894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.